Cognitive
Dihexa
Orally active angiotensin IV analogue with potent hepatocyte growth factor (HGF) mimetic activity.
- Route
- Oral or transdermal
Overview
Dihexa (N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide) is a small peptide developed at Washington State University for cognitive disorders. It is unusual in being orally bioavailable and BBB-permeable.
Mechanism of action
Enhances HGF binding to the c-Met receptor, driving synaptogenesis and dendritic spine formation. Reported 7 orders of magnitude more potent than BDNF in some spinogenesis assays.
Evidence base
Rodent Alzheimer models show restored learning and memory. No human clinical trials published as of 2026.
Typical dosing
Preclinical translations often cite 8–45 mg orally daily, though robust human data are lacking. Open the dose calculator →
Safety & contraindications
Human safety essentially unknown. Growth-factor amplification raises theoretical malignancy concern.
Related peptides
Educational reference only. Nothing on this page is medical advice, a prescription, or an offer to sell. Discuss any peptide therapy with a qualified clinician who can evaluate your history and monitoring needs.